Corbus`s lead drug succeeds in mid-stage scleroderma study

Published 9y ago

Corbus Pharmaceuticals Holdings Inc said its lead drug outperformed a placebo in a mid-stage study involving patients with a form of systemic sclerosis, an incurable autoimmune condition caused by abnormal growth of connective tissue. More »